Clinical relevance of circulating nucleosomes in cancer.

PubWeight™: 1.23‹?› | Rank: Top 10%

🔗 View Article (PMID 18837945)

Published in Ann N Y Acad Sci on August 01, 2008

Authors

Stefan Holdenrieder1, Dorothea Nagel, Andreas Schalhorn, Volker Heinemann, Ralf Wilkowski, Joachim von Pawel, Hannelore Raith, Knut Feldmann, Andreas E Kremer, Susanne Müller, Sandra Geiger, Gerhard F Hamann, Dietrich Seidel, Petra Stieber

Author Affiliations

1: Institute of Clinical Chemistry, University Hospital of Munich, Munich, Germany. Stefan.Holdenrieder@med.uni-muenchen.de

Articles citing this

Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol (2009) 1.95

HMGB1 in health and disease. Mol Aspects Med (2014) 1.67

Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res (2010) 1.28

The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci (2013) 1.25

Release and activity of histone in diseases. Cell Death Dis (2014) 1.10

Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression. BMC Cancer (2011) 1.02

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. Br J Cancer (2011) 1.00

Polyphosphate amplifies proinflammatory responses of nuclear proteins through interaction with receptor for advanced glycation end products and P2Y1 purinergic receptor. Blood (2013) 0.96

Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy. BMC Cancer (2012) 0.94

Circulating nucleic acids as biomarkers in breast cancer. Breast Cancer Res (2013) 0.94

Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology. Onco Targets Ther (2013) 0.92

Renal Dnase1 enzyme activity and protein expression is selectively shut down in murine and human membranoproliferative lupus nephritis. PLoS One (2010) 0.90

Colorectal carcinoma: nucleosomes, carcinoembryonic antigen and ca 19-9 as apoptotic markers; a comparative study. J Biomed Sci (2011) 0.89

Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer. Neoplasia (2011) 0.87

High-resolution characterization of sequence signatures due to non-random cleavage of cell-free DNA. BMC Med Genomics (2015) 0.87

Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget (2016) 0.85

DAMPs, ageing, and cancer: The 'DAMP Hypothesis'. Ageing Res Rev (2014) 0.81

Circulating nucleic acids in plasma and serum: diagnosis and prognosis in cancer. EPMA J (2010) 0.81

Serum DNA motifs predict disease and clinical status in multiple sclerosis. J Mol Diagn (2010) 0.80

Silver Nanoscale Hexagonal Column Chips for Detecting Cell-free DNA and Circulating Nucleosomes in Cancer Patients. Sci Rep (2015) 0.78

Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic. Expert Rev Hematol (2014) 0.76

Circulating nucleosomes as predictive markers of severe acute pancreatitis. J Intensive Care (2016) 0.76

Circulating Nucleosomes and Nucleosome Modifications as Biomarkers in Cancer. Cancers (Basel) (2017) 0.75

Protocol Outlines for Parts 1 and 2 of the Prospective Endoscopy III Study for the Early Detection of Colorectal Cancer: Validation of a Concept Based on Blood Biomarkers. JMIR Res Protoc (2016) 0.75

A novel method for isolation of histones from serum and its implications in therapeutics and prognosis of solid tumours. Clin Epigenetics (2017) 0.75

A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. Br J Cancer (2013) 0.75

Circulating nucleosomes are associated with mortality in pediatric acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol (2016) 0.75

The interaction between prognostic and pharmacodynamic biomarkers. Br J Cancer (2013) 0.75

Articles by these authors

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 17.30

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol (2004) 12.89

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet (2005) 12.30

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet (2009) 8.73

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol (2009) 7.80

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol (2003) 5.84

Histone recognition and large-scale structural analysis of the human bromodomain family. Cell (2012) 5.15

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol (2011) 5.06

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol (2006) 4.70

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol (2006) 4.58

Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91

Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol (2006) 3.52

Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell (2009) 3.51

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol (2011) 3.24

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A (2007) 3.21

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 3.13

HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep (2004) 3.00

Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol (2011) 2.92

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res (2004) 2.81

Magnetic resonance colonography for the detection of colorectal neoplasia in asymptomatic adults. Gastroenterology (2013) 2.71

Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med (Berl) (2007) 2.69

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol (2011) 2.69

The (un)targeted cancer kinome. Nat Chem Biol (2010) 2.33

Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ Res (2005) 2.32

Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer (2012) 2.30

Pruritus in cholestasis: facts and fiction. Hepatology (2014) 2.20

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist (2005) 2.17

Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin Cancer Res (2006) 2.13

Expression pattern of the transcription factor Olig2 in response to brain injuries: implications for neuronal repair. Proc Natl Acad Sci U S A (2005) 2.09

Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs (2007) 2.08

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol (2010) 2.05

Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res (2002) 1.95

The beta-lactam antibiotic, ceftriaxone, dramatically improves survival, increases glutamate uptake and induces neurotrophins in stroke. J Hypertens (2008) 1.91

Hsp70 chaperones as modulators of prion life cycle: novel effects of Ssa and Ssb on the Saccharomyces cerevisiae prion [PSI+]. Genetics (2004) 1.90

Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. J Hypertens (2008) 1.81

Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol (2006) 1.80

Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol (2006) 1.77

Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer (2006) 1.75

Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol (2006) 1.73

Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol (2007) 1.67

Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. Clin Chem (2011) 1.64

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol (2009) 1.64

Treatment of basilar artery embolism with a mechanical extraction device: necessity of flow reversal. Stroke (2002) 1.63

Cholangiocarcinoma. Crit Rev Oncol Hematol (2008) 1.59

Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology (2006) 1.58

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol (2012) 1.55

The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev (2013) 1.54

PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Cancer Res (2013) 1.53

Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol (2012) 1.52

Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia. Onkologie (2007) 1.51

Mechanical extraction of a basilar-artery embolus with the use of flow reversal and a microbasket. N Engl J Med (2002) 1.49

Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst (2003) 1.49

Effect of a glucose impulse on the CcpA regulon in Staphylococcus aureus. BMC Microbiol (2009) 1.46

SH2 domains: modulators of nonreceptor tyrosine kinase activity. Curr Opin Struct Biol (2009) 1.45

Structural and functional characterization of the human protein kinase ASK1. Structure (2007) 1.42

Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy? Onkologie (2007) 1.42

Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels. Anticancer Drugs (2013) 1.42

Clinical use of circulating nucleosomes. Crit Rev Clin Lab Sci (2009) 1.41

Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer (2012) 1.40

A new concurrent chemotherapy with vinorelbine and mitomycin C in combination with radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Onkologie (2005) 1.39

Readmissions of patients with diabetes mellitus and foot ulcers after infra-popliteal bypass surgery - attacking the problem by an integrated case management model. Vasa (2013) 1.38

Soluble MICA in malignant diseases. Int J Cancer (2006) 1.36

Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol (2005) 1.36

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci U S A (2013) 1.35

Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res (2008) 1.35

Prion variant maintained only at high levels of the Hsp104 disaggregase. Curr Genet (2005) 1.33

Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. J Clin Oncol (2011) 1.32

Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med (2009) 1.31

Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial. Cancer Sci (2013) 1.31

Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol (2013) 1.30

Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol (2013) 1.29

Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. JOP (2006) 1.27

Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR. Clin Chem (2005) 1.27

The role of the octarepeat region in neuroprotective function of the cellular prion protein. Brain Pathol (2007) 1.25

Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med (2003) 1.25

Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One (2012) 1.25

Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals. Scand J Gastroenterol (2010) 1.24

The long acidic tail of high mobility group box 1 (HMGB1) protein forms an extended and flexible structure that interacts with specific residues within and between the HMG boxes. Biochemistry (2004) 1.24

Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc (2014) 1.23

Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol (2007) 1.23

Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res (2008) 1.22

OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res (2008) 1.20

AXIS: a trial of intravenous granulocyte colony-stimulating factor in acute ischemic stroke. Stroke (2010) 1.19